BioVie Valuation Multiples
Discover BioVie's revenue and EBITDA valuation multiples and M&A history.
BioVie Overview
About BioVie
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Founded
2013
HQ
Employees
13
Website
Financials (LTM)
EV
$3M
Valuation Multiples
Start free trial
BioVie Financials
BioVie reported last 12-month revenue of $2M.
In the same LTM period, BioVie generated had net loss of ($22M).
BioVie P&L
In the most recent fiscal year, BioVie reported revenue of - and EBITDA of ($22M).
BioVie is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
BioVie Stock Performance
BioVie has current market cap of $12M, and enterprise value of $3M.
BioVie's stock price is $1.56.
BioVie has an EPS (earnings per share) of $-2.93.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3M | $12M | 1.3% | - | - | - | $-2.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioVie Valuation Multiples
BioVie trades at 1.5x EV/Revenue multiple, and (0.1x) EV/EBITDA.
BioVie Financial Valuation Multiples
As of August 14, 2026, BioVie has market cap of $12M and EV of $3M.
BioVie has a P/E ratio of (0.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioVie Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioVie Margins & Growth Rates
BioVie Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
BioVie Operational KPIs
BioVie's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
BioVie Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all BioVie competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by BioVie
BioVie has acquired 1 company to date.
Last acquisition by BioVie was on April 18th 2016. BioVie acquired LAT Pharma for undisclosed valuation.
Latest Acquisitions by BioVie
| Description | LAT Pharma is a San Diego-based biopharmaceutical company developing treatments for liver cirrhosis complications, primarily ascites. Its lead pre-IND candidate targets late-stage disease lacking approved therapies. The firm collaborates with PharmaIN Corporation in Bothell, Washington, on novel compounds for liver disorders, addressing a condition contributing significantly to US mortality. |
| HQ Country |  |
| HQ City | Chicago, IL |
| Deal Date | 18 Apr 2016 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all BioVie acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioVie
| When was BioVie founded? | BioVie was founded in 2013. |
| Where is BioVie headquartered? | BioVie is headquartered in United States. |
| How many employees does BioVie have? | As of today, BioVie has over 13 employees. |
| Is BioVie publicly listed? | Yes, BioVie is a public company listed on Nasdaq. |
| What is the stock symbol of BioVie? | BioVie trades under BIVI ticker. |
| When did BioVie go public? | BioVie went public in 2014. |
| Who are competitors of BioVie? | BioVie main competitors include |
| What is the current market cap of BioVie? | BioVie's current market cap is $12M. |
| What is the current revenue of BioVie? | BioVie's last 12 months revenue is $2M. |
| What is the current EV/Revenue multiple of BioVie? | Current revenue multiple of BioVie is 1.5x. |
| Is BioVie profitable? | No, BioVie is not profitable. |
| What is the current net income of BioVie? | BioVie's last 12 months net income is ($22M). |
| How many companies BioVie has acquired to date? | As of August 2026, BioVie has acquired 1 company. |
| What was the largest acquisition by BioVie? | None of the M&A deals BioVie has completed have disclosed valuations. |
| What companies BioVie acquired? | BioVie acquired LAT Pharma. |
| In how many companies BioVie has invested to date? | BioVie hasn't invested in any companies yet (or none have been disclosed publicly). |
Lists including BioVie
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.